# Camizestrant, a next-generation oral SERD, versus fulvestrant in post-menopausal women with oestrogen receptor-positive, HER2-negative advanced breast cancer (SERENA-2): a multi-dose, open-label, randomised, phase 2 trial

*PRI Rank #2 · Topics and Trends in Most Cited Estrogen and related hormone effects Papers, Class of 2026*

*Canonical URL: https://pri.pepkio.com/top-papers/estrogen-and-related-hormone-effects/2026/rank-2*

| Field | Value |
| --- | --- |
| Rank | #2 |
| 18m citations | 70 |
| Journal | The Lancet Oncology |
| Year | 2024 |
| DOI | 10.1016/s1470-2045(24)00387-5 |
| Corresponding authors | Mafalda Oliveira |
| Institution | Vall d'Hebron Institute of Oncology, Spain |

**Ranking page:** [Topics and Trends in Most Cited Estrogen and related hormone effects Papers, Class of 2026](https://pri.pepkio.com/top-papers/estrogen-and-related-hormone-effects/2026)

**Paper link:** [10.1016/s1470-2045(24)00387-5](https://doi.org/10.1016/s1470-2045(24)00387-5)

## Topics

Camizestrant · selective estrogen receptor degrader · fulvestrant · estrogen receptor-positive breast cancer · HER2-negative breast cancer · advanced breast cancer · menopause · SERENA-2 · phase 2 trial · multi-dose comparison · selective estrogen receptor degrader

## Cite this ranking

```
Pepkio Research Index (PRI). Topics and Trends in Most Cited Estrogen and related hormone effects Papers, Class of 2026. https://pri.pepkio.com/top-papers/estrogen-and-related-hormone-effects/2026. Accessed 2026-07-31.

Zheng Su, Tinsley Li, Thematic Shifts in Early-High-Impact Cancer Genomics and Diagnostics Research: A Bibliometric and Semantic Analysis. bioRxiv 2026.07.04.736459; doi: https://doi.org/10.64898/2026.07.04.736459
```